{"transactions":[{"id":736368,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-16T20:15:22.000Z","date":"2026-06-16","kind":"sale","planned":false,"acquired":false,"shares":11,"price":1.1901,"value":13.0911,"ownership":{"direct":true},"balance_after":0,"source":{"system":"sec-edgar","filing":"0001493152-26-028884","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226028884/ownership.xml","form_type":"4"}},{"id":947019,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-07T01:00:09.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":2500,"derivative":{"exercise_price":2.18,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001493152-26-000697","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000149315226000697/ownership.xml","form_type":"4"}},{"id":951494,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2026-01-05T21:27:42.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2026."}],"balance_after":240000,"derivative":{"exercise_price":11.49,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":240000},"source":{"system":"sec-edgar","filing":"0001794284-26-000002","document":"form4-01052026_090134.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000179428426000002/form4-01052026_090134.xml","form_type":"4"}},{"id":1057830,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-22T20:30:13.000Z","date":"2025-08-21","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":739830,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-25-022760","document":"form4-08222025_040801.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022760/form4-08222025_040801.xml","form_type":"4"}},{"id":1057829,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:30:13.000Z","date":"2025-08-21","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":15,"value":187500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on May 22, 2025."}],"balance_after":10042,"source":{"system":"sec-edgar","filing":"0001415889-25-022760","document":"form4-08222025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022760/form4-08222025_040801.xml","form_type":"4"}},{"id":1057828,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-08-22T20:30:13.000Z","date":"2025-08-21","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":1.5,"value":18750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,618 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on June 30, 2025."}],"balance_after":22542,"source":{"system":"sec-edgar","filing":"0001415889-25-022760","document":"form4-08222025_040801.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925022760/form4-08222025_040801.xml","form_type":"4"}},{"id":1137191,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T21:00:06.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":false,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":752330,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001415889-25-014184","document":"form4-05222025_050501.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014184/form4-05222025_050501.xml","form_type":"4"}},{"id":1137190,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-22T21:00:06.000Z","date":"2025-05-20","kind":"sale","planned":false,"acquired":false,"shares":50000,"price":14.1033,"value":705165.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The weighted average sale price for the transaction reported was $14.1033 and the range of prices were between $14.10 and $14.115. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided."}],"balance_after":7424,"source":{"system":"sec-edgar","filing":"0001415889-25-014184","document":"form4-05222025_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014184/form4-05222025_050501.xml","form_type":"4"}},{"id":1137189,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-05-22T21:00:06.000Z","date":"2025-05-20","kind":"exercise","planned":false,"acquired":true,"shares":50000,"price":1.5,"value":75000.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 2,475 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan on December 31, 2024."}],"balance_after":57424,"source":{"system":"sec-edgar","filing":"0001415889-25-014184","document":"form4-05222025_050501.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925014184/form4-05222025_050501.xml","form_type":"4"}},{"id":1303557,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-01-14T23:49:55.000Z","date":"2025-01-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the option will vest in a series of twelve (12) successive substantially equal monthly installments, with the first installment vesting on the one month anniversary of the grant date and continuing to vest monthly thereafter, subject to Reporting Person's continuous service through each such vesting date."}],"balance_after":5000,"derivative":{"exercise_price":1.38,"expiration_date":"2035-01-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001654954-25-000396","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495425000396/section16.xml","form_type":"4"}},{"id":1314773,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2025-01-03T21:30:33.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":176700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to the option shall vest in a series of 48 equal monthly installments measured from January 1, 2025."}],"balance_after":176700,"derivative":{"exercise_price":10.71,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":176700},"source":{"system":"sec-edgar","filing":"0001415889-25-000460","document":"form4-01032025_040124.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588925000460/form4-01032025_040124.xml","form_type":"4"}},{"id":1336707,"issuer":{"id":79017,"kind":"organization","name":"NKGen Biotech, Inc.","symbol":"NKGN"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-11T02:56:38.000Z","date":"2024-12-06","kind":"grant","planned":false,"acquired":true,"shares":500000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On December 6, 2024, the Reporting Person was granted 500,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in 36 equal installments on the sixth of each month, beginning January 6, 2025, and ending December 6, 2027, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":500000,"derivative":{"exercise_price":0.438,"expiration_date":"2034-12-06","underlying":"Common Stock","underlying_shares":500000},"source":{"system":"sec-edgar","filing":"0001213900-24-107608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1794284/000121390024107608/ownership.xml","form_type":"4"}},{"id":1336706,"issuer":{"id":79017,"kind":"organization","name":"NKGen Biotech, Inc.","symbol":"NKGN"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-12-11T02:56:38.000Z","date":"2024-12-06","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On December 6, 2024, the Reporting Person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, with 40% vesting immediately as of the grant date, and the remaining options vesting in 20 equal installments on the sixth day of each month, beginning January 6, 2025, and ending August 6, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":300000,"derivative":{"exercise_price":1.62,"expiration_date":"2034-12-06","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001213900-24-107608","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1794284/000121390024107608/ownership.xml","form_type":"4"}},{"id":1384810,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-10-17T20:30:32.000Z","date":"2024-10-16","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Immediately exercisable."}],"balance_after":802330,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-025370","document":"form4-10172024_041028.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924025370/form4-10172024_041028.xml","form_type":"4"}},{"id":1384809,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-17T20:30:32.000Z","date":"2024-10-16","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":16,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024."}],"balance_after":4949,"source":{"system":"sec-edgar","filing":"0001415889-24-025370","document":"form4-10172024_041028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924025370/form4-10172024_041028.xml","form_type":"4"}},{"id":1384808,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-10-17T20:30:32.000Z","date":"2024-10-16","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":1.5,"value":18750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person inadvertently added the holdings of Scott 2008 Trust Dated 3/28/08 (the \"Trust\") as directly held on her Form 4 filed on August 20, 2024.  As of the date of that Form 4, the Reporting Person owned 8,250 shares indirectly through the Trust."}],"balance_after":17449,"source":{"system":"sec-edgar","filing":"0001415889-24-025370","document":"form4-10172024_041028.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924025370/form4-10172024_041028.xml","form_type":"4"}},{"id":1426540,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-21T22:49:47.000Z","date":"2024-08-20","kind":"exercise","planned":true,"acquired":false,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Immediately exercisable."}],"balance_after":814830,"derivative":{"exercise_price":1.5,"expiration_date":"2032-02-29","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001415889-24-021882","document":"form4-08212024_100844.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021882/form4-08212024_100844.xml","form_type":"4"}},{"id":1426539,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-21T22:49:47.000Z","date":"2024-08-20","kind":"sale","planned":true,"acquired":false,"shares":12500,"price":16,"value":200000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2024."}],"balance_after":13199,"source":{"system":"sec-edgar","filing":"0001415889-24-021882","document":"form4-08212024_100844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021882/form4-08212024_100844.xml","form_type":"4"}},{"id":1426538,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-08-21T22:49:47.000Z","date":"2024-08-20","kind":"exercise","planned":true,"acquired":true,"shares":12500,"price":1.5,"value":18750.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes  2,969 shares acquired under the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") on June 30, 2023 and 1,980 shares acquired under the ESPP on June 28, 2024."}],"balance_after":25699,"source":{"system":"sec-edgar","filing":"0001415889-24-021882","document":"form4-08212024_100844.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000141588924021882/form4-08212024_100844.xml","form_type":"4"}},{"id":1642523,"issuer":{"id":79017,"kind":"organization","name":"NKGen Biotech, Inc.","symbol":"NKGN"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-02-15T01:20:58.000Z","date":"2024-02-12","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On February 12, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On February 12, 2024, the reporting person was granted 300,000 options pursuant to the Company's 2023 Equity Incentive Plan, vesting in equal installments on the first of each month, beginning October 1, 2023, and ending October 1, 2026, subject to the Reporting Person's continued service with the Issuer on each respective vesting date."}],"balance_after":300000,"derivative":{"exercise_price":1.62,"underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001104659-24-024197","document":"tm246293-5_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1794284/000110465924024197/tm246293-5_4seq1.xml","form_type":"4"}},{"id":1685681,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-06T02:01:59.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 4, 2024."}],"balance_after":10000,"derivative":{"exercise_price":0.6099,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001654954-24-000297","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495424000297/section16.xml","form_type":"4"}},{"id":1687837,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2024-01-04T21:39:59.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option shall vest on January 1, 2025, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":200000,"derivative":{"exercise_price":5.58,"expiration_date":"2034-01-01","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001209191-24-000805","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919124000805/doc4.xml","form_type":"4"}},{"id":2062721,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock option (right to buy)","published_at":"2023-01-05T22:00:55.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on January 1, 2024, and the remaining shares will vest monthly thereafter over three years."}],"balance_after":50000,"derivative":{"exercise_price":8.42,"expiration_date":"2033-01-02","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-23-001933","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919123001933/doc4.xml","form_type":"4"}},{"id":2100071,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-12-01T21:31:51.000Z","date":"2022-11-29","kind":"purchase","acquired":true,"shares":8250,"price":6.2432,"value":51506.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is the weighted average price.  The shares were sold in multiple transactions at prices ranging from $6.16 to $6.26, inclusive.  Upon request by the Securities and Exchange Commission staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"By Scott 2008 Trust Dated 3/28/08."}],"balance_after":8250,"source":{"system":"sec-edgar","filing":"0001209191-22-059187","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122059187/doc4.xml","form_type":"4"}},{"id":2120028,"issuer":{"id":883,"kind":"organization","name":"ARS Pharmaceuticals, Inc.","symbol":"SPRY"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2022-11-10T23:00:12.000Z","date":"2022-11-08","kind":"grant","acquired":true,"shares":827330,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Received in exchange for a stock option to acquire 700,000 shares of common stock of ARS Pharmaceuticals, Inc. (\"ARS\") with the exercise price of $1.77 per share pursuant to an Agreement and Plan of Merger and Reorganization by and among ARS, the Issuer and Sabre Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), as amended (the \"Merger Agreement\"). Under the terms of the Merger Agreement, on November 8, 2022, Merger Sub merged with and into ARS (the \"Merger\"), with ARS surviving the Merger as a wholly-owned subsidiary of the Issuer.  Upon the closing of the Merger, each outstanding option to purchase shares of ARS common stock was assumed by the Issuer and converted into an option to purchase the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Silverback Therapeutics, Inc. to ARS Pharmaceuticals, Inc."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the option vest on the one year anniversary of the vesting commencement date and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments measured from the first anniversary of the vesting commencement date."}],"balance_after":827330,"derivative":{"exercise_price":1.5,"expiration_date":"2032-03-01","underlying":"Common Stock","underlying_shares":827330},"source":{"system":"sec-edgar","filing":"0001209191-22-056438","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1671858/000120919122056438/doc4.xml","form_type":"4"}},{"id":2140567,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-10-07T21:05:51.000Z","date":"2022-10-06","kind":"grant","acquired":true,"shares":11359,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"On October 6, 2022, the Reporting Person was granted 11,359 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":27145,"source":{"system":"sec-edgar","filing":"0001654954-22-013526","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422013526/section16.xml","form_type":"4"}},{"id":2210009,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2022-07-08T20:10:11.000Z","date":"2022-07-07","kind":"grant","acquired":true,"shares":9960,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On July 7, 2022, the Reporting Person was granted 9,960 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":15786,"source":{"system":"sec-edgar","filing":"0001654954-22-009454","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000165495422009454/section16.xml","form_type":"4"}},{"id":2300465,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-08T23:17:45.000Z","date":"2022-04-07","kind":"grant","acquired":true,"shares":5826,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On April 7, 2022, the Reporting Person was granted 5,826 Common Stock restricted units pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan."}],"balance_after":5826,"source":{"system":"sec-edgar","filing":"0000905718-22-000568","document":"dermata_fm4apr72022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000568/dermata_fm4apr72022.xml","form_type":"4"}},{"id":2444440,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-01-06T00:05:36.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing January 3, 2022."}],"balance_after":5000,"derivative":{"exercise_price":1.88,"expiration_date":"2032-01-02","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000905718-22-000044","document":"dermata_fm4jan32022.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571822000044/dermata_fm4jan32022.xml","form_type":"4"}},{"id":2600571,"issuer":{"id":8182,"kind":"organization","name":"Dermata Therapeutics, Inc."},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to Buy)","published_at":"2021-08-17T16:47:00.000Z","date":"2021-08-17","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in twelve equal monthly installments commencing September 17, 2021."}],"balance_after":10000,"derivative":{"exercise_price":7,"expiration_date":"2031-08-17","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000905718-21-001106","document":"dermata_fm4aug172021.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1853816/000090571821001106/dermata_fm4aug172021.xml","form_type":"4"}},{"id":3365530,"issuer":{"id":112047,"kind":"organization","name":"Histogen Inc.","symbol":"HSTO"},"owners":[{"id":37735,"kind":"person","name":"Scott Kathleen D.","position":1,"cik":"0001794284","reported_name":"Scott Kathleen D.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-11-19T16:10:50.000Z","date":"2019-11-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option become exercisable as they vest. One-third of the total number of shares subject to this option vests and becomes exercisable on each anniversary of the grant date, so that the entire number of shares subject to this option becomes fully vested and exercisable on the third anniversary of the grant date."}],"balance_after":30000,"derivative":{"exercise_price":0.33,"expiration_date":"2029-11-17","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-19-057129","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1383701/000120919119057129/doc4.xml","form_type":"4"}}]}